Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to assess the efficacy of Quetiapine extended release
600mg per day either as monotherapy or combined therapy in the treatment of patients with
mania associated to Bipolar disorder. This trial will also assess the life quality and
productivity loss improvement for patients from baseline to day 21.